23.06.2022 22:05

Johnson & Johnson Renews Commitment to Fight Neglected Tropical Diseases, Investing in Beating Intestinal Worms, Dengue and Leprosy

NEW BRUNSWICK, N.J., June 23, 2022 – Johnson & Johnson proudly joined the global community, including governments, foundations, non-profit organizations and other pharmaceutical companies, to endorse the Kigali Declaration on Neglected Tropical Diseases. Together, we are recommitting to our long-established efforts to control and eliminate neglected tropical diseases (NTDs), a set of debilitating diseases that put at risk the health of 1.7 billion people around the world, especially the most vulnerable and underserved.Working from the lab to the last-mile of health delivery, Johnson & Johnson is today committing to fight the neglect impacting three major public health challenges: intestinal worms (soil-transmitted helminths or STH), dengue and leprosy. Endorsing the Kigali Declaration, the Johnson & Johnson Family of Companies commits to:Donate up to 200 million doses annually of mebendazole, our Janssen Pharmaceutical Companies’ medicine to treat intestinal worms, through 2025; and to Advance novel R&D programs to discover new medicines needed to beat dengue and leprosy.These diseases are a cause of significant illness, disability and death, especially among children in some of the world’s poorest and most vulnerable communities. Dengue is resurging in endemic countries and expanding into new regions as a result of the climate crisis, and leprosy is one of the world’s most ancient diseases that has yet to be eliminated. For more than 15 years, Johnson & Johnson has been at the forefront of global efforts to beat NTDs, proudly donating more than two billion doses of mebendazole for the treatment of intestinal worms to field partners in more than 50 countries. This was further bolstered by the development of a new chewable formulation of mebendazole in 2019 that can be easily administered to children as young as one year of age, supporting the training of community health workers, enabling better data management and supporting the development of new diagnostics. Through tireless and collaborative efforts, countless children in need have been given the opportunity to recover, play, learn – and thrive. In 2012, Johnson & Johnson joined the global community in launching the landmark London Declaration on NTDs, a first-of-its-kind, public-private partnership aimed at addressing the burden of NTDs. This coordinated action has proven to be one of the most impactful global public health collaborations, resulting in 40 countries eliminating at least one neglected tropical disease since 2012 and hundreds of millions of people no longer at risk.We have an historic opportunity to unlock the potential of hundreds of millions of lives and create a prosperous and safer future for communities across the globe. That is why we are in this fight and invite you to join us in beating NTDs. To learn more, visit JNJ.com/NTDs. ###Cautions Concerning Forward-Looking StatementsThis press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding neglected tropical diseases (NTDs), including soil-transmitted helminths, dengue and leprosy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceutica N.V., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; [manufacturing difficulties and delays;] competition, including technological advances, new products and patents attained by competitors; challenges to patents; [product efficacy or safety concerns resulting in product recalls or regulatory action;] changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
Weiter zum vollständigen Artikel bei "Johnson & Johnson"
Ausgewählte Hebelprodukte auf Johnson & Johnson
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Johnson & Johnson
Hebel wählen:
Quelle: EN, Johnson & Johnson

Nachrichten zu Johnson & Johnson

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Johnson & Johnson

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
01.06.2021JohnsonJohnson OutperformCredit Suisse Group
13.10.2020JohnsonJohnson OutperformCredit Suisse Group
27.08.2019JohnsonJohnson kaufenGoldman Sachs Group Inc.
27.08.2019JohnsonJohnson OutperformCredit Suisse Group
16.07.2019JohnsonJohnson OutperformCredit Suisse Group
01.06.2021JohnsonJohnson OutperformCredit Suisse Group
13.10.2020JohnsonJohnson OutperformCredit Suisse Group
27.08.2019JohnsonJohnson kaufenGoldman Sachs Group Inc.
27.08.2019JohnsonJohnson OutperformCredit Suisse Group
16.07.2019JohnsonJohnson OutperformCredit Suisse Group
23.01.2019JohnsonJohnson Equal WeightBarclays Capital
21.07.2016JohnsonJohnson HoldDeutsche Bank AG
13.06.2016JohnsonJohnson NeutralGoldman Sachs Group Inc.
27.01.2016JohnsonJohnson HaltenIndependent Research GmbH
21.01.2016JohnsonJohnson HaltenIndependent Research GmbH
17.04.2018JohnsonJohnson SellGoldman Sachs Group Inc.
21.07.2017JohnsonJohnson SellBTIG Research
20.05.2016JohnsonJohnson SellStandpoint Research
17.10.2012JohnsonJohnson verkaufenIndependent Research GmbH
10.10.2012JohnsonJohnson sellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Johnson & Johnson nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Börse Stuttgart Anlegerclub

Heute im Fokus

DAX im Plus -- Delivery Hero bestätigt vorläufige Zahlen -- DWS holt Digitalisierungsexperten von der Deutschen Bank -- Walmart, Bayer, Fresenius Medical Care, Infineon, Philips im Fokus

BHP hat im vergangenen Geschäftsjahr so viel verdient wie noch nie zuvor. Home Depot profitiert von Heimwerker-Nachfrage. Fitch bestätigt Bonitätsnoten für Allianz. Hauck Aufhäuser Investment Banking belässt VERBIO auf 'Buy'. EnBW will größten Solarpark im Südwesten bauen. Tencent will offenbar milliardenschwere Beteilung an Meituan abtreten.


Sollten die Corona-Regeln bei steigenden Infektionszahlen im Herbst wieder verschärft werden?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln